Lead Product(s): PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Undisclosed Product Type: Large molecule
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 04, 2020
Financing will be used to strengthen POINT’s position as a leader in radioligand development which includes PNT2002, a 177Lu-PSMA radiotherapeutic to treat prostate cancer and commercialization through investment in their pipeline as well as manufacturing capabilities.